Rasburicase 

Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout^[1][2][3].

Rasburicase (0.2 mg/kg；静脉注射；每日 1 次；5-7 天) 快速降低裸鼠肿瘤溶解综合征 (TLS) 模型的血尿酸水平，预防尿酸结晶沉积及肾损伤^[1]。
Rasburicase (100 μg；静脉注射；3 次；第 -3、0、+3 天) 在小鼠中抑制抗 Rasburicase 抗体产生，减少脾脏抗原特异性 B 细胞和 T 细胞数量，上调调节性 T 细胞 (Treg) 比例^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

134774-45-1

无菌粉末

White to off-white

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cammalleri L, et al. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007 Mar 2;4(2):83-93.  [Content Brief]

  [2]. Xu H, et al. High-Dose IV Administration of Rasburicase Suppresses Anti-rasburicase Antibodies, Depletes Rasburicase-Specific Lymphocytes, and Upregulates Treg Cells. AAPS J. 2020 May 27;22(4):80.  [Content Brief]

  [3]. Kono H, et al. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 2010 Jun;120(6):1939-49.  [Content Brief]